Pulse check on Lilly's GLP-1 fortunes
The Top Line27 Mars

Pulse check on Lilly's GLP-1 fortunes

While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a crack in the company’s armor may be forming, according to at least one analyst. As that assessment dealt a blow to the company’s stock price in recent weeks, Lilly is plowing forward all the same with more details on its next wave of potential incretin drugs.

In this week’s episode of "The Top Line," the Fierce Pharma team breaks down Lilly’s recent HSBC downgrade, what it signals for the GLP-1 and obesity markets, and the data shaping the company’s next wave of diabetes and weight loss products. Fierce’s Eric Sagonowsky is joined by Kevin Dunleavy and Fraiser Kansteiner to unpack the latest and assess the commercial narrative around GLP-1s so far.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(100)

How we picked the Fierce 15

How we picked the Fierce 15

What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.In this wee...

9 Okt 23min

Locking in on pharma’s consumerization trend

Locking in on pharma’s consumerization trend

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing opportunities in an evolving m...

2 Okt 18min

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In this episode of "The Top...

25 Sep 24min

Inside the growing world of biopharma prediction markets

Inside the growing world of biopharma prediction markets

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researche...

18 Sep 23min

Clinical trials reach a new automation inflection point (Sponsored)

Clinical trials reach a new automation inflection point (Sponsored)

Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual process...

14 Sep 17min

The future of RAS inhibitors

The future of RAS inhibitors

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach...

11 Sep 29min

The people who stayed with the problem

The people who stayed with the problem

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vacci...

4 Sep 25min

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In...

2 Sep 13min

Populärt inom Politik & nyheter

svenska-fall
fordomspodden
motiv
rss-krimstad
p3-krim
aftonbladet-krim
flashback-forever
aftonbladet-daily
spar
svd-dokumentara-berattelser-2
rss-sanning-konsekvens
rss-vad-fan-hande
rss-krimreportrarna
omni-podd
svd-ledarredaktionen
rss-flodet
kungligt
de-fyras-gang
ett-rent-noje
politiken